Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 7/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.46 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3603394 | 0.83 | HRH3 (0.59) | ACHEHRH3KDM4EGAAMAPT | |
| SCHEMBL3407025 | 0.77 | PIK3CA (0.49) | ACHEHRH3PIK3CAEHMT2KDM4E | |
| SCHEMBL25013983 | 0.76 | PIK3CB (0.43) | ACHEPIK3CBPIK3CAEHMT2BACE1 | |
| SCHEMBL25014025 | 0.76 | ACHE (0.49) | ACHEPIK3CBPIK3CAEHMT2BACE1 | |
| SCHEMBL25013984 | 0.75 | KDM1A (0.48) | ACHEPIK3CBEHMT2BACE1 | |
| SCHEMBL25013924 | 0.75 | PIK3CB (0.45) | ACHEPIK3CBPIK3CAEHMT2BACE1 | |
| SCHEMBL25013933 | 0.75 | CXCR4 (0.45) | ACHEPIK3CBEHMT2BACE1 | |
| SCHEMBL25013943 | 0.75 | CXCR4 (0.44) | ACHEPIK3CBPIK3CAEHMT2BACE1 | |
| SCHEMBL6980975 | 0.75 | HRH3 (0.76) | ACHEHRH3KDM4EGAABACE1 | |
| SCHEMBL25014024 | 0.74 | PIK3CB (0.42) | ACHEHRH3PIK3CBPIK3CAEHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256143-A1 | PHARMACEUTICAL COMPOUNDS | BAKER STEWART JAMES | 2010-10-07 | — | — | US | disclosed |
| EP-2146981-A1 | PHARMACEUTICAL COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008125833-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256143-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, JAK2 | ACHE 3051/4885HRH3 1633/4885PIK3CB 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.